Report Highlights Research Needed To Foster Generic Drug Development

October 2017

Pharmaceutical News

Country of origin: USA

The US Food and Drug Administration (FDA) recently issued the ?Critical Path Opportunities for Generic Drugs? report identifying many of the unanswered scientific questions that impede the development of generic versions of commonly used drugs.

The report is part of FDA?s Critical Path Initiative, established in 2004 to discern what challenges exist in moving a promising drug, biologic or device along the critical path from discovery, or proof of concept, to a marketable product.

Solving these challenges will require the expertise and input of many groups, including scientists from universities, patient groups, government, industry, associations and other private organisations.

?This report pinpoints the barriers that are limiting the availability of additional generic drug options,? said Gary Buehler, R.Ph., director, FDA?s Office of Generic Drugs. ?We hope these findings will encourage research collaboration, lower these barriers and accelerate access to safe and effective generic drugs.?

Before they can be approved, generic drugs must have the same active ingredient, dosage form, strength, and conditions of use as the brand name drug. The drugs must also be absorbed at the same rate and in the same amount, a concept known as bioequivalence.

While straightforward tests of blood plasma levels are sufficient to demonstrate bioequivalence for most generic drug candidates, these common tests generally are not appropriate for certain drugs, including asthma inhalers, nasal sprays, and topical skin applications such as anti-fungal creams. As a result, few generic versions are available in these product categories, resulting in less competition and higher prices.

For example, generic drug products that contain the ozone-depleting substance chlorofluorocarbon will be withdrawn from the market after 2008.
The new report will help ensure FDA has an adequate scientific basis to review inhaler applications that use an alternative, hydrofluoroalkane.

The report also calls for research on new bioequivalence methods tailor-made for each challenging drug class. These include lung function tests and molecular level imaging for inhalation drugs; particle size distribution tests for nasal sprays; and methods for direct measurement of drug delivered to the skin.

In addition, the report highlights possible research projects that might lead to new modeling and simulation tools for drug absorption, drug release and other drug development issues and to alternative methods for seeking waivers from clinical bioequivalence studies.

During 2006 FDA issued the Critical Path Opportunities Report listing 76 specific scientific projects that, if undertaken, would help modernise the Critical Path sciences. This companion document focuses more narrowly on the scientific challenges unique to the development of generic drugs.

Resources

Monthly Prescribing Reference January 2018 The MPR App is your all-in-one drug information resource accessible anytime, anywhere. The 30th Anniversary Edition of the...
Infectious Disease Advisor January 2018 Infectious Disease Advisor is a free, simple to use, medical app that offers infectious disease specialists and other...
Clinical Pain Advisor January 2018 Clinical Pain Advisor is a free, simple to use, medical app that offers pain medicine healthcare professionals a...
Endocrinology Advisor January 2018 Endocrinology Advisor is a free, simple to use, medical app that offers endocrinologists, diabetes educators and other...
Psychiatry Advisor January 2018 Psychiatry Advisor is a free, simple to use, medical app designed to be the essential resource for psychiatric healthcare...
The Drugs & Bugs app January 2018 The Drugs & Bugs app by Monthly Prescribing Reference (MPR) is an essential resource for allied healthcare professionals,...
Pandemic Influenza Surge Capacity And Prioritisation In Health Services December 2017 A document has been published which is designed to give guidance on managing the surge capacity needed to respond to an...
Reducing the Inappropriate Use of Antibiotics December 2017 The National Public Health Service for Wales (NPHS) has published its second annual report from its Antimicrobial...
ASPET Pharmacology and Experimental Therapeutics September 2017 The American Society for Pharmacology and Experimental Therapeutics (ASPET) is organised into a 'public'section, which...
Genetic roadmap charts links between drugs and human disease September 2017 A research team led by scientists at the Broad Institute of MIT and Harvard has developed a new kind of genetic ?roadmap?...
Search by Keyword